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INTRODUCTION 
                  Analytical chemistry may be defined as the science and art of 
determining the composition of materials in terms of the elements of 
composition contained. Pharmaceutical analysis is a bench of science that deals 
with the analytical procedures used to determine the purity, safety and quality 
of drugs and chemicals. It  contains  procedures  to  determine  the  identity , 
strength , quality and purity of new  compounds . It also involves procedures 
for separating, identifying, and determining the relative amount of the 
components in sample of matter.  
                 Quality assurance plays a key role in finding the safety and 
efficiency of medicines. It has  highly  specific  and  sensitive  analytical 
methods  for  the  design , development, standardization and quality control of 
medicinal products . They are equally important for the pharmacokinetics and 
drug metabolism studies, both which are important for the assessment of 
bioavailability and clinical response.  
                  Modern physical method of analysis are extremely sensitive even 
for small amount of samples of materials .It can be rapidly applied and can 
readily amenable to automation. So it is widely used in the product 
development and in the control of manufacture , formulation and also in 
monitoring the use of drugs and medicines.  
                 The term  pharmaceutical  analysis  includes both quantitave and 
qualitative analysis of Drugs  and  pharmaceutical  substances  starting from 
bulk drugs to finished dosage forms .So it is  used  as  a  diagnostic  aids  in the  
modern  practice  of medicine by the  analysis of chemical constituents in the 
human body  which may alter during the disease state . 
                 If the quality of drug product is questioned by a physician , the 
pharmacist is responsible for  taking  necessary  steps  to  determine  if  indeed  
the  product  is  defective . This  may  be accomplished  by  contacting with 
drug manufacturer about the problem involving the product , analyzing  the  
preparation  in  the  laboratory , borrowing  needed  equipment  from  a  
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clinical laboratory   if  necessary , sending  the  sample  to  a  private  
laboratory  for  analysis , or  a combination of all these steps .In any case 
,however, it remains the responsibility of analyst to solve  problems  relating  to  
drug  quality .  
                The  term ‘quality’ as  applied  to  a  drug  product  has  been defined 
as the sum of all factors which contributes directly or indirectly to the safety , 
effectiveness and reliability of the product. 
 Significance of quality control: 
               The pharmaceutical industry continues as a vital segment of the health 
care cycle in conducting research and manufacturing products which are life 
maintaining and life restoring.  
                 Modern  medicines  for  human  use  are required to meet exacting 
standards which are Related  to  their  quality , safety  and efficacy .The  
evaluation  of  safety , efficacy and their maintenance  in practice is  dependent 
up on  the  existence of adequate methods for the quality control of product.  
              Quantitative  analysis  reveals  the  chemical identity  of  species  in  
the  sample . Quantitative analysis establishes the relative amount of one or 
more of these species or analyte in numerical terms.  
Analytical Techniques 
                The efficacy and safety of a medicinal product can only be 
assured by analytical monitoring of its quality. Therefore, the overall purity 
of a medicine must be assessed throughout its storage, distribution and use. 
               The objective can possibly be achieved if the specification to be 
applied are based on  validated  procedure , which  can  demonstrate the 
relationship in quality between the  substance  under  examination  and that 
initially subjected to pharmaceutical, toxicological  and pharmacological 
evaluation. 
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               These   are   the   following   techniques   employed for   
estimation of   different components in formulations. 
Optical methods 
Some of the optical methods are 
 X-ray spectroscopy 
 UV-Visible spectroscopy 
 Infrared spectroscopy 
 Atomic absorption spectroscopy 
 Flame  photometry 
 Nuclear magnetic resonance spectroscopy 
 Nephlo-turbidimetry 
 Electron spin spectroscopy 
Electro analytical methods: 
 Some of the electro analytical methods are 
 Amperometry 
 Voltametry 
 Potentiometry 
 Conductometry 
Separation methods/chromatography 
 Some of chromatographic methods are 
 Gas-liquid chromatography 
 Gas-solid chromatography 
 Liquid-liquid chromatography 
 Liquid-solid chromatography 
 Thin-layer chromatography 
 Paper chromatography 
 Gel permeation chromatography 
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               One of the major decisions to be made by an analyst is the choice of 
the most effective procedure  for a given analysis ,  for this he  must be  
familiar with the practical details, the  theoretical  principles  and  also  that  he  
must  be  conversant  with  the condition  under which each method is reliable , 
aware of possible interferences which may arise and  capable of demising 
means of circumventing such problems .   
The instrumental separative techniques are divided into two categories. 
1. Chromatography 
2. Electrophoresis 
3. Mass spectroscopy 
Chromatography 
                Chromatography is a technique by which a mixture is separated into 
its components as a result of  the  relative  ability  of each component to be 
eluted along or through the stationary phase by mobile phase .The sample  is 
placed on edge of the stationary phase (a solid or liquid) and a mobile  phase is 
allowed to flow over the stationary phase to sweep the sample along the length 
of the stationary phase .Component which are strongly adsorbed to the 
stationary phase are swept less rapidly along the length of the stationary phase 
than those components that are less strongly adsorbed to stationary phase . 
              The word chromatography is derived from the Greek letters chromos   
meaning colour and the graphy means colour writing. The initial use of the 
terms is attributed to Tswett,  who separated colour bands of plant pigments on 
a chromatography column that consist of an adsorbent powder that was washed 
with a liquid solvent termed as mobile phase . This is carried down the length 
of the tube that contains an immobile solid or liquid phase i.e. stationary phase.   
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 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
              The technique of high performance liquid chromatography (HPLC) 
was developed in the later 1960s and early 1970s from knowledge of the 
theoretical principles that already had been established for earlier 
chromatographic techniques in particular for column chromatography. The 
technique is based on the same modes of separation as classical column 
chromatography. I.e. adsorption, partition (including reverse phase partition), 
ion exchange and gel permeation. HPLC differ from column chromatography 
in that mobile phase is pumped through the packed column under high 
pressure. The principal advantages of HPLC compared to classical (gravity 
feed) column chromatography are improved resolution of the separated 
substances, faster separation times and the increased accuracy, precision and 
sensitivity with which the separated substances may be quantified. 
Basic principle of HPLC 
                    High performance liquid chromatography (HPLC) is a separation 
technique utilizing differences in distribution of compounds in phases called 
stationary phase and mobile phase. The stationary phase designates a thin layer 
created on the surface of fine particles and the mobile phase designates the 
liquid flowing over the particles. Under a certain dynamic solution, each 
component in a sample has different distribution equilibrium depending on the 
solubility in the phases and the molecular size.   
 
                   As a result, the component move at different speeds over the 
stationary phase and there by separated by each other. The column is a stainless 
steel (or resin) tube, which is packed with spherical solid particles. Mobile 
phase constantly fed into the column inlet at a constant rate by a liquid pump. 
Sample is injected from sample injector, located near the column inlet. The 
injected sample enters the column with mobile phase and the components in 
these samples migrate through it, passing between the stationary phase and 
mobile phase. 
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                      Compound move in the column only it is in the mobile phase and 
therefore migrate faster through the column while compounds that tend to be 
distributed in the stationary phase migrate slower .In this way, component is 
separated on the column and sequentially elutes from the outlet. A detector 
connected to the outlet of the column detects each compound eluting from the 
column.  
 
                   The recorder starts at the time when sample is injected and 
monitors the separation process and a graph is obtained. This graph is called 
chromatogram. The time that is required for a compound to elute (called 
retention time) and the relationship between the compound concentration 
(amount) and peak area depends on the characteristics of the compound. 
Selectivity of HPLC 
Most of the drugs can be analysed by HPLC method because of several 
advantages.  
 Speed (analysis can be accomplished in 20 minutes or less). 
 Greater sensitivity (various detectors can be employed). 
 Improved resolution (wide variety of stationary phase). 
 Reliable columns (wide variety of stationary phase). 
 Ideal for substances of low volatility.  
 Easy sample recovery, handling and maintenance. 
 Easy programming of the numerous functions in each module. 
  Time programmable operation sequence, such as initiating operation of 
detector lamp and pump to obtain stable baseline and equilibrated 
column before the work day begins. 
 Excellent reproducibility of retention time. 
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Different Modes of Separation of HPLC 
- Normal phase mode 
- Reverse phase mode 
- Reverse phase ion pair chromatography 
- Ion exchange chromatography 
- Affinity chromatography 
- Size exclusion chromatography (gel permeation and gel filtration 
chromatography) 
Instrumentation for HPLC 
- A solvent reservoir for the mobile phase to be delivered to column over 
a wide range of flow rates and pressure. A degasser is needed to remove 
dissolved air and other gases from the solvents 
- A pump to deliver the mobile phase to the column. The pumping system 
must be pulse free. A pump should be able to operate to at least 100 
atm(1500 psm), pressure suited to less expensive chromatography. 
However, 400 atm (600 psi) is a more desirable pressure limit. For many 
analytical columns only moderate flow rate of 0.5 to 2 ml per minute 
needed to be generated. 
- Sampling valves or loops are used to inject the sample in the flowing 
mobile phase just at the head of the separation column. 
- At the head of the separation column, there may be a guard column or a 
inline filter to prevent contamination of the main column by small 
particulates.  
- The separation column contains the packing needed to accomplish the 
desired HPLC separation. These may be silica’s for adsorption 
chromatography, bonded phases for liquid-liquid  chromatography, ion 
exchange functional groups bonded to stationary support for ion 
exchange chromatography, gels of specific porosity for exclusion 
chromatography, or some unique packing for a particular separation 
method. 
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- Most column lengths ranges from 10 – 30 cm, short, fast columns are 3 
– 8cm long with an internal diameter of 4 -5 mm. Particle diameter lie in 
the range 3 -5 µm, occasionally up to 10 µm or higher for preparative 
chromatography. 
- A detector with some type of data handling device, completes the basic 
instrumentation. 
The various detectors are 
- UV visible photometers 
- Refractive index detector 
- Flourimetric detector 
- Conductivity detector 
- Amperometric detector 
- PDA 
           Detector electronic integrators and computing integrators are 
widely used today in HPLC for measuring peak areas. These devices 
automatically sense peaks and print out the areas in numerical forms. 
With the help of peak areas and height values, the peak width can be 
calculated (considering the peak as a triangle) and it can also be used for 
the calculation of number of theoretical plates. 
Quantitation methods in HPLC 
                Peak heights or peak area measurements only provide a 
response in terms of detector signal.  
               This response must be related to the concentration or mass of 
the compound of interest. To accomplish this, some type of calibration 
must be performed.  
The four primary techniques for quantization are 
a. Normalized peak area method. 
b. External standard method. 
c. Internal standard method. 
d. Method of standard addition. 
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a) Normalized peak area method 
 The area percent of any individual peak is referred to as normalized 
peak area. This technique is widely used to estimate the relative amounts 
of small impurities or degradation compounds in a purified material and in 
this method the response factor for each component is identified. 
                 
b)    External Standard method 
           This method includes injection of both standard and unknown, and 
the unknown is determined graphically from a calibration plot or 
numerically using response factors. 
A response factor (RF) can be determined for each standard as follows. 
   RF   =   Standard area (peak height) / Standard Concentration 
 The external standard approach for most samples in HPLC that do not require 
extensive sample preparation. 
c) Internal Standard method 
   Internal standard is a different component from the analyte but one 
that is well resolved in the separation. The internal standard should be chosen 
to mimic the behavior of the sample component. One of the main reasons for 
using an internal standard is for samples requiring significant pre treatment or 
preparation. 
d) Method of standard addition 
           The method of standard addition can be used to provide a 
calibration plot for quantitative analysis. It is more often used in trace 
analysis. 
           An important aspect of the method of standard addition is that the 
response prior spiking additional analytes should be high enough to 
provide a reasonable S/N ratio (<10), otherwise the result will have poor 
precision. (Vogel’s 2003). 
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VALIDATION 
  
             Validation is a key process for effective quality assurance. “Validation 
is established documented evidence, which provides specific a high degree of 
assurance that a process of equipment will consistently produce a product or 
result meeting its predetermined specifications and quality attributes”. 
 
Definition 
               USFDA defines validation as “established documented evidence 
which provides a high degree of assurance that a specific process will 
consistently produce a product of predetermined specifications and quality 
attributes”. 
 
                 EUGMP defines validation as “action of proving in accordance with 
the principle of Good manufacturing practice (GMP), that any material activity 
or system actually lead to expected result”.  
 
                AUSTRALIAN GMP defines validation as “the action of proving 
that any material, process, procedure, system, equipment or mechanism used in 
manufacture or control can and will be reliable and achieve the desire and 
intended result”.  
Importance of validation 
1. As the quality of the product cannot be always assured by routine 
quality 
control because of testing of statistically insignificant number of sample. 
2. The validation should provide adequacy and reliability of a system or 
product to meet the predetermined criteria or attributes, providing high 
degree of confidence that the same level of quality is consistently build 
into each of finished product from batch to batch. 
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3. Retrospective validation is useful for trend comparison or results 
complaints to cGMP to cGLP. 
4. For taking appropriate action in case of non-compliance. 
  
Objectives of validation 
             The primary objective of validation is to form a basis for written 
procedure for production and process control which are designed to assure that 
the drug products have the identity, quality and purity they purport or are 
represented to possess. 
1. Assurance of quality. 
2. Government regulation. 
 
Types of validation 
The following are frequently required to be validated on a pharmaceutical 
process 
1. Equipment validation 
2. Process validation 
3. Cleaning validation 
4. Analytical method validation 
5. Facility validation including utilities 
 
ANALYTICAL METHOD VALIDATION  
                 Method validation is a process to confirm that the analytical 
procedure employed for a specific test is suitable for its intended use. 
Analytical testing of a pharmaceutical product is necessary to ensure the purity, 
stability, safety and efficacy. Analytical method validation is an integral part of 
the quality control system. 
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PARAMETERS USED FOR ASSAY VALIDATION 
 The validations of the assay procedure are carried out using following 
parameters.  
SPECIFICITY: 
                 Specificity is the ability to asses unequivocally analyte in the 
presence of impurities, degradants, matrix, etc which may be expected to be 
present. Lack of specificity of an individual analytical procedure may be 
compensated by other supporting analytical procedures.  
PRECISION: 
Definition  
                 The precision of an analytical procedure express the closeness of the 
agreement between a series of measurements obtained from multiple sampling 
of the same homogenous sample under the prescribed conditions. The precision 
of an analytical procedure is usually expressed as the variance, standard 
deviation or co-efficient of variation of a series measurement.  
System precision 
                 A system precision is evaluated by measuring the peak response for 
the six replicable injection of the same standard solution prepared as per the 
proposed method .The %RSD is calculated and it should not be more than 2%. 
Method precision 
                   A method precision is evaluated by measuring the peak response 
for six replicate injection of six different weigh of sample solution prepared as 
per proposed method. The %RSD is calculated and it should not be more than 
2%.  
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Determination 
 The precision of an analytical method is determined by assaying a 
sufficient number of aliquots of a homogenous sample to be able to calculate 
statistically valid estimates of standard deviation or relative standard deviation. 
ICH Requirements 
                 The ICH documents recommended that repeatability should be 
assessed using a minimum number of nine determinations covering the 
specified range of the procedure (I, e., three concentrations and there replicates 
of each concentrations or using a minimum of six determinations at 100% of 
the test concentration).  
ACCURACY 
Definition 
              The accuracy of an analytical procedure express the closeness of the 
agreement between the values which is acceptable either as conventional true 
value or an accepted reference value and the value found. 
Determination 
               In case of assay of drug in a formulated product ,accuracy may be 
determined by application of the analytical method to synthetic mixtures of the 
drug product components to which the known amount of analyte have been 
added within the range of the method . If it is not possible to obtain all product 
components ,it may be acceptable either to add known quantities of the analyte 
to the drug product or to compare results with those of a second ,well 
characterized method ,the accuracy of which has been stated or defined 
.Accuracy studies for drug substance and drug product are recommended to be 
performed at the 80,100 and 120% level of label claim as stated in the 
guidelines for submitting samples and analytical data for method validation .At 
each recommended level studied ,replicate samples are evaluated. The RSD of 
the replicates will provide the analysis variation or how precise the test method 
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is. The mean of the replicates, expressed as %label claim, indicates how 
accurate the test method is. 
ICH Requirements 
               The ICH documents recommended that accuracy should be assessed 
using a minimum of nine determinations over a minimum of three 
concentration levels, covering the specified range (i.e., three concentration and 
three replicates of each concentration). 
LINEARITY 
Definition 
             The linearity of an analytical procedure is its ability (with in a given 
range) to obtain the test results which are directly proportional to the 
concentration (amount) of analyte in the sample.                     
Determination 
             Linearity of an analytical procedure is established minimum of five 
concentrations. It is established initially by visual examination of plot of 
signals as a function of analyte concentration of content .If  there appears to be 
a linear relationship ,test results are established by appropriate statistical 
methods(i.e., by calculation of the regression line by the method of least 
squares). 
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LIMIT OF DETECTION (LOD) 
Definition 
          LOD is the lower concentration of the substance that the method can 
detect but not necessarily quantify.LOD simply indicates that the sample below 
or above a certain level. 
Determination                 
         For non instrumental methods, the detection limit is generally determined 
by the analysis of samples with known concentration of analyte and by 
establishing the minimum level at which the analyte can be reliably detected. 
ICH Requirements                          
              The ICH describes a common approach, which is to compare 
measured signal from samples with known concentrations of analyte with those 
of blank samples. The minimum concentration at which the analyte can reliably 
be detected is established. 
            Typically acceptable signal-to-noise ratios are 2:1 or 3:1. 
LIMIT OF QUANTITATION (LOQ) 
Definition 
              LOQ is the lowest concentration of the substance that can be estimated 
quantitatively with acceptable precision, accuracy and reliability by the 
proposed method. LOQ is determined by the analysis of samples containing 
decreasing known quantity of the substance and determining the lowest level at 
which acceptable level of accuracy and precision is attained. 
 Determination   
             For non-instrumental methods, quantization limit is generally 
determined by the analysis of samples with known concentration of analyte and 
by establishing the minimum level at which the analyte can be determined with 
acceptable accuracy and precision. 
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RANGE 
Definition  
            The range of an analytical procedure is the interval between the upper 
and the lower concentration (amounts) of analyte in the sample (including these 
concentrations) for which it has been demonstrated that the analytical 
procedure has a suitable level of precision, accuracy and linearity. 
Determination 
            The range of the method is validated by verifying that the analytical 
method provides acceptable precision, accuracy and linearity when applied to 
samples containing analyte at the extremes of the range as well as within the 
range. 
ROBUSTNESS 
Definition 
             The robustness of an analytical procedure is a measure of its capacity 
to remain unchanged by small but deliberately variations in method parameters 
and provides an indication of its reliability during normal usage. 
Determination 
             The robustness of method determined by performing the assay by 
deliberately altering parameters(change in flow rate ±10%,change in mobile 
phase ratio  ±2,change in pH of mobile phase ±0.2,change in wave length 
detection  ±5nm, change in temperature ±1 to 50 ) that the results are not 
influence by the changes in the above parameters. 
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RUGGEDNESS 
Definition 
           The ruggedness of an analytical method is the degree of reproducibility 
of test results obtained by the analysis of the samples under a variety of 
conditions, such as different laborites, different analyst, different instruments, 
different lots of reagents, different elapsed assay times, different assay 
temperatures, different days etc. 
Determination 
             The ruggedness of analytical method is determined by the analysis of 
aliquots from homogenous lots in different laboratories, by different analysis, 
using operational and environmental condition that may differ but are still 
within the specified parameters of the assay .The degree of reproducibility of 
the results is that determined as a function of assay variables. This 
reproducibility may be compared to the precision of assay under normal 
condition to obtain a measure of the ruggedness of the analytical method.  
 
SAMPLE SOLUTION STABILITY 
            Solution stability of the drug substance or drug product after 
preparation according to the test method should be evaluated. Most laboratories 
utilize auto samples with overnight runs and the sample will be in solution for 
hours in the laboratory environment before the rest procedure is completed. 
This is concern especially for drugs that can undergo degradation by 
hydrolysis, photolysis, and adhesion to glassware.   
SYSTEM SUITABILITY SPECIFICATION AND TESTS 
            The accuracy and precision of HPLC data collected begin with a well 
behaved chromatographic system. The system suitability specifications and 
tests are parameters that provide assistance in achieving this purpose. 
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It consists of following factors: 
1. Capacity factor 
2. Precision\Injection repeatability 
3. Relative retention 
4. Resolution 
5. Tailing factor 
6. Theoretical plate number 
1. Capacity factor (K’) 
                                                  K’ = (tR-tO/tf) 
            The capacity factor is a measure of where the peak of interest is located 
with respect to the void volume i.e., elution time of the non retained 
components. 
 
2. Precision/Injection repeatability (RSD) 
                    Injection precision expressed as RSD (relative standard deviation) 
indicates the performance of the HPLC which includes the pumping, column 
and the environmental conditions, at the time the samples are analyzed .It 
should be noted that sample preparation and manufacturing variations are not 
considered. 
3. Relative retention (α) 
                                            α   =   K’1/K’2  
                 Relative retention is a measure of the relative location of two peaks. 
This is not an essential parameter as long as the resolution (Rs) is stated.  
4. Resolution (Rs) 
                                         Rs = (tR2-tR1)/(1/2)(tw1+tw2) 
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                Rs is a measure of how well two peaks are separated. For reliable 
quantitation well separated peaks are essential for quantitation. This is a very 
useful parameter if potential inference peaks (s) may be concern.  
5. Tailing factor 
                                       T = Wx/2f 
                  The accuracy of quantitation decreases with increases in peak 
tailing because of the difficulties encountered by the integrator in determine 
where/when the peak ends and hence the calculation of the area under the peak. 
Integrator variables are present by the analyst for optimum calculation of the 
area for the peak of interest. If the integrator is unable to determine exactly 
when an upslope for down slope occurs, accuracy drops.  
6. Theoretical plate number (N) 
                                                 N = 16(tR/tw) 2 = L/H 
                               Theoretical plate number is a measure of column efficiency, 
that is, how many peaks can be located per unit run-time of the chromatograph. 
               N- Constant for each peak on the chromatogram with a fixed set of 
operating conditions. 
               H- Height equivalent of a theoretical plate.       
               L- Length of column. 
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                                                   LITERATURE REVIEW 
K.S. LAKSHMI et al., (2009)  have been developed a simple, sensitive 
and rapid reverse phase high performance liquid chromatographic method was 
developed for the estimation of Metformin Hcl (MET) and Pioglitazone (PIO) 
in pure and in pharmaceutical dosage forms. A Gemini C18 column 
(150x4.6mm, 5μ) was used with a mobile phase containing a mixture of 
Acetonitrile and Ammonium Acetate buffer (pH-3) in the ratio of 42: 58. The 
flow rate was 0.3ml/min and effluents were monitored at 255nm and eluted at 
5.17min (MET) and 8.1min (PIO). Calibration curve was plotted with a range 
from 0.5-50 μg/ml for MET and 0.3-30 μg/ml for PIO. The assay was validated 
for the parameters like accuracy, precision, robustness and system suitability 
parameters. The proposed method can be useful in the routine analysis for the 
determination on metformin and pioglitazone in pharmaceutical dosage forms. 
S Havele et al., (2010) have developed a simple, rapid, and precise 
reversed-phase high-performance liquid chromatographic method for 
simultaneous analysis of metformin hydrochloride, gliclazide, and pioglitazone 
hydrochloride in a tablet dosage form has been developed and validated. 
Chromatography was performed on a 25 cm × 4.6 mm i.d., 5-
column with 85:15 (v/v) methanol: 20 mM potassium dihydrogen phosphate 
buffer as mobile phase at a flow rate of 1.2 ml/min. UV detection at 227 nm; 
metformin hydrochloride, gliclazide, and pioglitazone hydrochloride were 
eluted with retention times of 2.15, 3.787, and 4.57 min, respectively. The 
method was validated in accordance with ICH guidelines. Validation revealed 
the method is specific, rapid, accurate, precise, reliable, and reproducible. 
Calibration plots were linear over the concentration ranges 50– 
metformin hydrochloride, 3.0 – r gliclazide, and 2–
pioglitazone hydrochloride. Limits of detection were 0.20, 0.04, and 0.10 
metformin hydrochloride, gliclazide, and pioglitazone hydrochloride, 
respectively. The high recovery and low coefficients of variation confirm the 
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suitability of the method for simultaneous analysis of the three drugs in tablets. 
Statistical analysis proves that the method is suitable for the analysis of 
metformin hydrochloride, gliclazide, and pioglitazone hydrochloride as a bulk 
drug and in pharmaceutical formulation without any interference from the 
excipients. It may be extended to study the degradation kinetics of three drugs 
and also for its estimation in plasma and other biological fluids 
 
G Mubeen et al., (2010) have been developed a simple 
Spectrophotometric method has been developed and validated for the 
estimation of Metformin hydrochloride in bulk and in tablet formulation. The 
primary amino group of Metformin hydrochloride was oxidized using 
hydrogen peroxide to form a yellow chromogen , which is determined 
spectrophotometrically at 400 nm. It obeyed Beer’s law in the range of 4-
26mcg/ml.The percentage recovery of the drug for the proposed method ranged 
from 99-101.3% indicating no interference of the tablet excipients. The 
proposed method was found to be accurate and precise for routine estimation of 
Metformin hydrochloride in bulk and in tablet dosage forms. 
MARIA-CRISTINA RANETTI et al., (2009) have been developed a 
simple HPLC method for the simultaneous determination of metformin (MTF) 
and gliclazide (GCZ) in the presence of glibenclamide, in human plasma, for 
the clinical monitoring of MTF and GCZ after oral administration or for 
bioequivalence studies. Ion-pair separation followed by UV detection 
performed on deproteinised plasma samples was chosen for the determination 
of metformin and gliclazide.The mobile phase was acetonitrile: methanol 
(1:1v/v) and sodium dodecylsulphate 5mM, pH=3.5 with H3PO4 85% and 
gradient elution. The eluent was monitored at 236 nm. The calibration curve 
was linear within the range of 0.05-5.00 μg/mL (r2=0.99, n=6). The lowest 
limit of quantification (LLOQ) was 50 ng/mL for metformin and 49 ng/mL for 
gliclazide.The proposed method was validated and proved to be adequate for 
metformin and gliclazide clinical monitoring, bioavailability and 
bioequivalence studies. 
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DRUG PROFILE 
METFORMIN HCL 
               Structure 
   
N
CH
3
NH
N
H
NH
2
CH
3
NH
 
                                          
    
Molecular Formula             : C14H11N5.HCL 
Molecular weight                :  165.62g/mol 
IUPAC Name                      : :N,N-dimethylimidodicarbonimidic diamide 
 
Solubility                            : Freely soluble in  water; slightly soluble in 
Ethanol; 
                                               
Category                              : Anti -diabetic 
Dose                                     25 to 100 mg 
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Mechanism of action: 
Metformin improves hyperglycemia primarily through its suppression of 
hepatic glucose production (hepatic gluconeogenesis. The "average" person 
with type 2 diabetes has three times the normal rate of gluconeogenesis; 
metformin treatment reduces this by over one third. Metformin activates AMP-
activated protein kinase (AMPK), a liver enzyme that plays an important role 
in insulin signaling, whole body energy balance, and the metabolism of glucose 
and fats, activation of AMPK is required for metformin's inhibitory effect on 
the production of glucose by liver cells. Research published in 2008 further 
elucidated metformin's mechanism of action, showing activation of AMPK is 
required for an increase in the expression of SHP, which in turn inhibits the 
expression of the hepatic gluconeogenic genes PEPCK and Glc-6-Pase. 
Metformin is frequently used in research along with AICAR as an AMPK 
agonist. The mechanism by which biguanides increase the activity of AMPK 
remains uncertain; however, research suggests that metformin increases the 
amount of cytosolic AMP (as opposed to a change in total AMP or total 
AMP/ATP. 
Adverse effects: 
The   most   common   adverse   effect   of   metformin is gastrointestinal 
upset, including diarrhea, cramps, nausea, vomiting and increased flatulence; 
metformin is more commonly associated with gastrointestinal side effects than 
most other antidiabetic drugs.  
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SITAGLIPTIN   
Structure: 
N
N
N
N
O
F
F
F
F
F
F
NH
2
 
 
Molecular formulae              : C16H15F6N5O           
Molecular Weight                 : 407.314 
IUPAC Name                        : (R)-4-oxo-4-[3-(trifluoromethyl)-5,6                
                                                  dihydro[1,2,4]triazolo[4,3-a]pyrazin         
                                                  7(8H)-yl]-1-(2,4,5-)butan-2-amine. 
 
Category                               : Antidabetic  
Dose                                      : 25 to 100 mg. 
 
Solubility                              : Soluble in water and N,N Dimethyl formamide;                   
Storage                                : Store in well-closed containers.  
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PHARMACOLOGY: 
Mechanism of action: 
Sitagliptin works to inhibit the enzyme dipeptidyl peptidase 4 (DPP-4). 
This enzyme breaks down the incretins GLP-land GIP, gastrointestinal 
hormones released in response to a measure. By preventing GLP-1 and GIP 
inactivation, they are able to potentiate the secretion of insulin and suppress the 
release of glucagon by the pancreas. This drives blood glucose levels towards 
normal. As the blood glucose level approaches normal, the amounts of insulin 
released and glucagon suppressed diminishes, thus tending to prevent an 
"overshoot" and subsequent low blood sugar (hypoglycemia) which is seen 
with some other oral hypoglycemic agents 
Side effects: 
The most common side effects of sitagliptin are abdominal pain, nausea 
diarrhea, vomiting and hypoglycemia. Lactic acidosis is a serious side effect of 
metformin that occurs in one out of every 30,000 patients and is fatal in 50% of 
cases. The symptoms of lactic acidosis are weakness, trouble breathing, 
abnormal heartbeats, unusual muscle pain stomach discomfort, light-
headedness and feeling cold. Patients at risk for lactic acidosis include those 
with reduced function of the kidneys or liver, congestive heart failure severe 
acute illnesses, and dehydration. 
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AIM AND PLAN OF WORK 
         The drug analysis is playing an important role in the development of 
drugs, their manufacture and therapeutic use. For the simultaneous estimation 
of drugs present in dosage forms , lot of suitable methods are adopted like  uv –
spectrophotometer , HPLC , HPTLC etc .These methods are powerful and 
rugged method .They are also extremely precise, specific, accurate, linear and 
rapid.  
           A pharmaceutical industry depends upon quantitative chemical analysis 
to ensure that the raw material used and the final product obtained meets the 
required specification. The drugs will occur as a single component or multi 
component dosage forms. The later proves to be effective due to its combined 
mode of action on the body.  
         The number of drugs or drug formulations introduced into the market is 
increasing at a fast rate .These may be either new entries in the market or 
structural modification of the existing drugs or novel dosage forms or multi 
component dosage forms .The complexity in the dosage forms, including that 
of the multi component dosage forms creates considerable challenges to the 
analytical chemist during the development of assay procedure for its accurate 
estimation. The estimation of individual drugs in these multi component dosage 
forms becomes difficult due to tedious extraction or isolation procedure. 
         The combination of   Metformin HCL and Sitagliptin was selected for the 
present study.  
         According to the literature survey conducted, it was observed that no 
method was reported in RP-HPLC for the estimation of individual drug carried 
out. Hence present study aims to develop an accurate, precise, specific, linear, 
simple, rapid, validated and cost effective analytical method for Metformin 
HCL and Sitagliptin  in tablet dosage form by RP-HPLC method. The scope of 
our work extends to validate for the developed method as per ICH guidelines.  
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RP-HPLC method development was obtained as  
 Selection and optimization of mobile phase and stationary phase. 
 Selection of detector wavelength. 
 Selection of extraction procedure. 
 Optimization of chromatographic condition. 
 Estimation of Metformin HCL and Sitagliptin  
 Method validation. 
                                            MATERIALS AND METHODS 
Instrumentation: 
S.No. Name of instrument Model Make 
1 Semi micro balance CPA225D Sartorius 
2 pH meter Metler Toledo Thermo Orion 
3 HPLC LC-20 AT Shimadzu 
4 C 18 Column Phenomenex Gemini 
5 Sonicator USB Spectro lab 
6 UV 1700 series Shimadzu 
 
Chemicals and reagents: 
S.No. Chemicals/Reagents Make/grade 
1  Glacial acetic acid Merck(HPLC Grade) 
2 Dipotassium  hydrogen phosphate Merck(GR Grade) 
3 Methanol Merck(GR Grade) 
4 water Merck(GR Grade) 
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Working/Reference Standards: 
S.No Name of Working/reference standards % Purity 
1  Metformin HCL Working standard 99.65 
2  Sitagliptin Working standard 99.61 
 
 Filters: 
S 
.No 
Name of the filter 
1. 0.45 m GHP membrane filter(Manufactured by PALL) 
    
                            METHOD DEVELOPMENT GUIDE 
                        Information on sample, define separation goals. 
                                                    
                            Need for special procedure, sample treatment. 
 
   Choose detector and detector settings. 
 
Choose the method: preliminary run: estimate the best separation condition 
  
                                    Optimize separation conditions. 
  
       Validate the method. 
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                                                      Table-1      
 
Goal 
 
Comment 
Resolution 
Precise and rugged quantitative analysis requires that Rs 
be greater than 1.5. 
Separation time <5-10 min is desirable for routine procedures 
Quantitation 
≤2% for assays ;≤5% for less demanding analysis 
 
≤15% for trace analyses. 
pressure 
<150 bar is desirable, <200 bar is usually essential (new 
column assumed). 
Peak height Narrow peaks are desirable for large signal /noise ratios. 
Solvent 
consumption 
Minimum mobile-phase use per run is desirable. 
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POLARITY OF COMMON ORGANIC FUNCTIONAL GROUPS AND 
SOLVENTS 
Functional Groups                         Non-Polar                     Solvent                                            
Aliphatic hydrocarbons                                                   Hexane 
Olefines Carbon tetrachloride 
Aromatic hydrocarbons Ester 
Halides Benzene 
Sulphides Methyl chloride 
Ethers THF 
Nitro components Isopropanol 
Esters, aldehydes, ketones Chloroform 
Alcohols, amines Ethylacetate 
Sulphones Acetonitrile 
Sulphoxides Methanol 
Amides Water 
Carboxylic acids 
                                                                Polar 
 
   
 
 
 
 
  
31 
 
OPTIMIZATION OF CHROMATOGRAPHIC CONDITIONS 
1. Selection of wavelength for detection of components 
               Solution of  Metformin HCL and Sitagliptin were scanned in the UV 
region and spectrum was recorded .The solvent used was 0.02M dipotassium 
hydrogen phosphate,and acetonitrile in the ratio 55:45. It was seen that at 
260nm all compounds have good absorbance, which can be used for the 
estimation of compounds by HPLC. 
 
2. Selection of chromatographic method 
           Proper selection of the method depends on the nature of the sample 
(ionic or ionisable or neutral molecules), its molecular weight, pka value and 
stability .The drugs selected in the present study are polar and so reversed 
phase or ion exchange chromatography can be used. The reverse phase HPLC 
was selected for the initial separation because of its simplicity and suitability. 
 
           For the literature survey and with knowledge of properties of the 
selected drugs, Phenominex Gemini C18 (250 × 4.6mm) 5µ column was 
chosen as stationary phase and mobile phase with different compositions such 
as Acetonitrile was used. The separations were not observed so use of buffer 
was finalized. 
 
           For all the data observed, obtained and available the initial separation 
condition were set to work around.    
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3. Initial separation condition      
          The following chromatographic conditions were fixed initially to 
improve the separation of both drugs.  
Instrument                              : Shimadzu prominence 
Column                                  : Phenomenex Gemini C18 (250 × 4.6mm), 5µ. 
Column oven temperature     : Ambient 
Wavelength                           : 260nm 
Flow rate                               : 1.2ml/min 
Injection volume                   : 20µl 
Run time                                : 10 min 
Mobile phase                         : Solvent A - Buffer            
                                                Solvent B - Methanol 
                                                Solvent C - Acetonitrile 
Solvent Ratio                       : 30:35:35% V/V of A: B: C 
TRAILS 
Trail-1 
          The trail was performed using Mobile phase in the ratio 30:35:305using 
Phenomenex C18 (250 x 4.6 mm, 5μ) with flow rate of 1.2ml/min.  
          In this trail, the retention time ofMetformin HCL and Sitagliptin peak 
was found to be 0.9, and 4.0 min respectively.  
Trail-2 
        The trail 2 was performed using Mobile phase in the ratio 30:40:30 using 
Phenomenex C18 (250x 4.6 mm, 5μ) with flow rate of 1.2 ml/min.  
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        In this trail, the retention time of Metformin HCL and Sitagliptin  peak 
was found to be 0.7 and2.4  min. respectively.  
Trail-3 
         The trail 3 was performed using Mobile phase in the ratio 55:45of using 
Phenomenex C18 (250 x 4.6 mm, 5 μ) with flow rate of 1 ml/min.  
        In this trail, the retention time of Metformin HCL and Sitagliptin peak was 
found to be 4.28and 7.485min respectively. 
Trial-4: 
          The trail 4 was performed using Mobile phase in the ratio of 40:40 
:20using Phenomenex (250 x 4.6 mm, 5 μ) with flow rate of 1 ml/min.  
          In this trail, only two peaks were shown at 2 and 3.2 min. 
         Out of 4 trails made in the lab, the 3th trail was selected for further studies 
because when compared to other trails, the 3th trail was found to be having less 
retention time and within the acceptance criteria.  
4. Effect of ratio of mobile phase 
            Under the chromatographic conditions mentioned above the different 
ratios of mobile phase were tried .The chromatograms where observed for each 
of the trials, out of which 30: 35:35 i.e.; 30 Buffer: 35 Methanol: 35 
Acetonitrile was selected as the separation was achieved in minimum retention 
time. 
5. Effect of pH of mobile phase 
           Several trials were made using different buffer solutions of pH range 
.The best separation was achieved when adjusted the pH to 4.5 with 
orthophosphoric acid. 
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6. Effect of flow rate on separation  
            The mobile phase consisting of buffer: methanol: acetonitrile was used 
and the chromatograms were recorded at flow rates of 1ml/min, 1.2ml/min. The 
sharpest peaks were obtained with 1.5ml/min flow rate. 
7. Effect of column (stationary phase) on separation  
          At the chromatographic conditions of mixed solutions, combination of 
Metformin HCL and Sitagliptin were injected and chromatograms were 
obtained using C-18 columns. 
8. Reference standards 
        Keeping all other above fixed conditions, external standard was used.  
9. Optimized condition  
      The following optimized parameters were used in a final method for the 
simultaneous estimation of Metformin HCL and Sitagliptin. 
Instrument                               : Shimadzu Prominence 
Column                                   : Phenominex C18 (250 × 4.6mm), 5µ. 
Column oven temperature     : Ambient 
Wavelength                            : 260nm 
Flow rate                                : 1ml/min 
Injection volume                    : 20µl 
Run time                                : 10 min 
Mobile phase                         : Solvent A - Buffer            
                                               Solvent B- Acetonitrile 
Solvent Ratio                        : 55:45% V/V of A: B 
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QUANTITATION 
Samples obtained from  local market.  
 Metformin HCL -500mg 
Sitagliptin-50mg 
 
Preparation of Dipotassium  hydrogen phosphate buffer pH 4.5: 
         Prepare about 0.02M dipotassium hydrogen phosphate in a suitable 
conical flask and adjust the pH to 4.5 with orthophosphoric acid.(0.02M of di 
potassiumhydrogen phosphate is prepared by taking 1.3602mg of  
dipotassiumhydrogen phosphate in a volumetric flask , and make up to 1L with 
water).  
Preparation of mobile phase: 
         Prepare a mixture of buffer 4.5 pH,  and acetonitrile in the ratio 55:45 
filter through 0.45µ membrane filter and degas it. 
Diluent preparation: Buffer 4.5 pH, and acetonitrile in the ratio 55:45 
 
Standard preparation: 
               Weigh accurately about  50mg of Metformin, 50mg  Sitagliptin 
working standard to a 100ml volumetric flask.Dissolve it completely and 
sonicate it. Make up to 100ml mobile phase. Take 3ml from the above flask 
and make up to 50ml with mobile phase. 
Sample preparation: 
               Weigh accurately 20 tablets equivalent to 92.4mg to a 100ml 
volumetric flask.mobile phase to dissolve it completely and sonicate for 10min 
with intermediate shaking Make up to 100ml with mobile phase and filter 
through 0.45µ GHP filter. Further dilute 3ml with 50ml mobile phase. 
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Calculation: 
              Determine the % amount of Metformin HCL and Sitagliptin  
  in tablets according to the following formula. 
     AT ×W R × 3 × 100 × 50 × PR × Average Weight 
 %Assay =        × 100 
 AR × 100 × 50 × WT × 3 × 100 × LA 
Where,AT = Area in the test solution  
AR = Area in the standard solution 
WR = Weight of standard solution (mg) 
WT = Weight of sample in test preparation (mg) 
PR = Purity of working standard (%) 
LA = Labeled amount of Metformin HCL and Sitagliptin  per Tablets. 
 
           VALIDATION OF THE DEVOLOPED METHOD 
SPECIFICITY 
           Specificity is the ability to measure accurately and specifically the 
analyte of interest in the presence of other components that may be expected to 
be present in the sample matrix. The other component may include excipients, 
impurities, degradation product etc. 
           Peak purity test may be useful to show that the analyte chromatographic 
peak is not contributed by more than one component (e.g. .diode array, mass, 
spectroscopy). 
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 Standard preparation: 
                           Weigh accurately about  50mg of Metformin, 50mg  
Sitagliptin working standard to a 100ml volumetric flask.Dissolve it completely 
and sonicate it. Make up to 100ml mobile phase. Take 3ml from the above 
flask and make up to 50ml with mobile phase. 
                                                                Table - 2 
Sample Metformin HCL Sitagliptin 
 Avg area 
%Drug 
Content 
Avg area 
%Drug 
Content 
Standard 352.914 
 
100.18 
440.46 
 
99.67 
  Sample 354.469 436.16 
       
 
Acceptance Criteria: 
           There is no interference in the standard peak. 
LINEARITY: 
        Linearity is the ability of the method to elicit test results that are directly 
proportional to analyte concentration within a given range. 
 
         Linearity is generally reported as the variance of the slope of the 
regression line. Linearity should be evaluated by visual inspection of a plot of 
signal as a function of analyte concentration. The correlation coefficient, y-
intercept, slope of the regression line and the residual sum of squares should be 
calculated. 
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Linearity of Metformin HCL and Sitagliptin   
    Weigh accurately about  50mg of Metformin, 50mg  Sitagliptin working 
standard to a 100ml volumetric flask.Dissolve it completely and sonicate it. 
Make up to 100ml mobile phase. Take 3ml from the above flask and make up 
to 50ml with mobile phase. 
Table - 3 
LEVEL  Metformin Sitagliptin 
80% 1773.542 164.743 
90% 1996.980 1848.657 
   100% 2221.836 2053.140 
110% 2466.998 2251.260 
   120% 2663.495 2478.061 
Y – intercept 1548 1430 
Slope 22.48 207.7 
Correlation 
Coefficient 
0.999 0.999 
 
Linearity Graph 
RANGE: 
             Range is the interval between the upper and the lower levels of analyte 
that have been demonstrated to be determined with precision, accuracy and 
linearity using the method.  
             The range is normally expressed in the same unit as the test results 
obtained by the method. The ICH guideline specify a minimum of five 
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concentration levels, along with certain minimum specified ranges .For assay 
tests the minimum specified range is 80 – 120%of the target concentration . 
Preparation of working standard solution 
              To get a concentration of 80%, 100%, 120%, of drug, pipette out 4ml, 
5ml, 6ml, of mixed standard stock solution into separate 100ml volumetric 
flask and volume is made up with mobile phase.  Further dilute 3ml of the 
solution to 100ml of mobile phase. 
Acceptance Criteria: 
 The %RSD for the individual recoveries of each level and mean 
recovery should not be more than 2.0%. 
 The % recovery at each level and mean recovery should be in 
between 98.0% to 102.0%.  
LIMIT OF DETECTION (LOD) 
                  The limit of detection (LOD) is defined as the lowest concentration 
of an analyte in a sample that can be detected, though not necessarily 
quantitated. It is a limit test that specifies whether or not an analyte is above or 
below a certain value.  
             ICH has recommended some method for determining the limit of 
detection. The method may be either instrumental or non-instrumental. They 
are 
 Visual Evaluation 
 Signal – to – Noise ratio convention 
 Based on Standard deviation of the response and the slope of 
calibration curve  
 
Limit of detection (LOD) based on standard deviation of the response and 
the slope of calibration curve. 
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                                    3.3 s 
                                             LOD   =    
           S 
 Where  
              s = Standard deviation of the response 
              S = Slope of calibration curve 
                                         
Table - 4 
Limit of detection study: 
 
LOD Metformin HCL:(µg) Sitagliptin(µg) 
1. 1.05 7.12 
 
LIMIT OF QUANTITATION (LOQ) 
             The limit of Quantitation (LOQ) is defined as the lowest concentration 
of the analyte in a sample that can be determined with acceptable precision and 
accuracy under the stated operational conditions of the method. 
               Limit of Quantitation (LOQ) is also based on standard deviation of 
the response and the slope of calibration curve. 
                                                                        10 s 
                                                    LOQ =     
        S 
  Where,  
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                               s = Standard deviation of the response           
 S = Slope of calibration curve 
                                        Table - 5 
Limit of Quantitation study: 
LOQ Metformin HCL(µg) Sitagliptin(µg) 
1. 5.6 3.5 
 
PRECISION 
                 Precision is the measure of the degree of repeatability of an analyte 
method under normal operation and is normally expressed as percent relative 
standard deviation for a significant number of the samples. 
                According to the ICH precision should be performed at three 
different levels: Repeatability, Intermediate precision, Reproducibility 
System precision 
             The system precision was evaluated by measuring the peak response of 
Metformin HCL and Sitagliptin Hydrochlorothiazide,  WS solution prepared as 
per the proposed method and chromatograms were recorded.   
 
Determination 
                                                Weigh accurately about  50mg of Metformin, 
50mg  Sitagliptin working standard to a 100ml volumetric flask.Dissolve it 
completely and sonicate it. Make up to 100ml mobile phase. Take 3ml from the 
above flask and make up to 50ml with mobile phase. 
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s.no Metformin Sitagliptin 
1 
 
2051.31 2218.08 
2 2061.14 2228.22 
3 2047.51 2230.72 
4 2055.83 2229.53 
5 2043.94 2212.8 
6. 2039.57 2217.84 
AVG 2049.88 2222.86 
STD/%RSD 0.33/0.33 0.37/0.38 
 
Method Precision 
      Weigh accurately 20 tablets equivalent to 92.4mg to a 100ml volumetric 
flask.mobile phase to dissolve it completely and sonicate for 10min with 
intermediate shaking Make up to 100ml with mobile phase and filter through 
0.45µ GHP filter. Further dilute 3ml with 50ml mobile phase. 
Table - 6 
Method Precision for Metformin HCL: 
 
Sample. No 
 
% Assay 
Sample Preparation – 1 100.14 
Sample Preparation – 2 100.1.8 
Sample Preparation – 3 100.71 
Sample Preparation – 4 100.76 
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Sample Preparation – 5 100.51 
Sample Preparation – 6 100.56 
Avg 100.76 
SD 0.688 
% RSD 0.70 
                                         
Table - 7 
Method Precision for  Sitagliptin: 
 
Sample. No 
 
% Assay 
Sample Preparation – 1 97.67 
Sample Preparation – 2 98.60 
Sample Preparation – 3 97.62 
Sample Preparation – 4 98.65 
Sample Preparation – 5 97.20 
Sample Preparation – 6 97.24 
Avg 97.80 
SD 0.712 
% RSD 0.730 
 
Acceptance Criteria: 
 The % RSD for the individual recoveries of each level and mean 
recovery should not be more than 2 %. 
 The % recovery at each level and mean recovery should be in between 
98.0% to 102%. 
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ACCURACY 
           Accuracy is the measure of exactness of an analytical method, or the 
closeness of agreement between the measured value and the value that is 
accepted either as a conventional, true value or an accepted reference value.  
           The accuracy may be determined by application of analytical method to 
an analyte of known purity (example: reference standard) and also by 
comparing the results of the method those obtained using an alternative 
procedure that has been already validated.  
          To document accuracy, the ICH guideline on methodology recommends 
collecting data from a minimum of nine determinations over a minimum of 
three concentration levels covering the specified range. 
Result: Refer range of calculations. 
Preparation of working standard solution 
             To get a concentration of 80%, 100%, 120% of drug, pipette out 4ml, 
5ml, 6ml, of mixed standard stock solution into separate 100ml volumetric 
flask and volume is made with mobile phase. Further dilute 3ml this solution to 
50ml with mobile phase. 
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Recovery values of  Sitagliptin 
 Table 8 
Concentration Avg Area 
Amount 
Recovery 
% Recovery 
80 1679.874 3.96 99.78 
100 2086.258 4.96 99.24 
120 2565.329 6.08 101.18 
Mean 100.06 
SD 0.79 
%RSD 0.79 
                                                             
                                                           Table – 9 
Recovery values of  Metformin 
Concentration Avg Area 
Amount 
Recovery 
% Recovery 
80 1777.467 39.89 99.93 
100 2210.760 49.50 99.05 
120 2694.174 59.99 100.03 
Mean 99.66 
SD 0.44 
%RSD 0.44 
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Acceptance Criteria: 
 The % RSD for the individual recoveries of each level and mean 
recovery should not be more than 2 %. 
 The % recovery at each level and mean recovery should be in between 
98.0% to 102%. 
 
ROBUSTNESS 
Robustness is the capacity of a method to remain unaffected by small 
deliberate variations in method parameters. 
 
The robustness of a method is evaluated by varying method parameters 
such as percent organic solvent, pH, ionic strength or temperature and 
determining the effect on the results of the method. Robustness tests were 
generally introduced to avoid problems in linear laboratory studies and to 
identify the potentially responsible factors. 
Determination of robustness 
       Robustness was performed by varying the  
- PH  
- Flow rate  
 
Table - 10 
Robustness study for Metformin HCL and Sitagliptin: 
Robustness Criteria 
RT of 
Metformin 
RT of 
Sitagliptin 
Change in flow +0.2 3.707 6.100 
Change in flow -0.2 4.790 7.560 
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Change in wavelength by -PH 4.27 7.44 
Change in wavelength by + PH 4.28 7.48 
 
Acceptance Criteria: 
 Shall comply the system suitability parameters.  
 Measured variation to be reported with appropriate recommendations 
RUGGEDNESS 
             Ruggedness of analytical method is the degree of reproducibility of the 
results obtained by the analysis of the same samples under a variety of test 
conditions such as different laboratories, analysts, instruments, temperature, 
different days etc.  
 
Determination of Ruggedness 
             The Ruggedness of an analytical method was determined by the 
analysis of aliquots from homogenous lots in different laboratories by different 
analysts using operational and environmental condition that may differ but are 
still within the specified parameters of the assay. The degree of reproducibility 
of the results is then determined as a function of assay variables. This 
reproducibility may be compared to the precision of assay under normal 
condition to obtain a measure of the ruggedness of the analytical method.  
 
                To determine the degree of reproducibility of the results by this 
method involved the studies of the analyst to analyst and day to day; that is to 
carry out precision study in six replicate of an assay of a single batch sample by 
two different analysts on two different days.  
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Ruggedness Interday Analysis Study :( Table –11 ) 
Sample. No 
% Assay of 
Metformin HCL 
% Assay of  
Sitagliptin 
Analyst – 1 98.9 102.0 
Analyst – 2 99.2 100.1 
Analyst – 3 99.7 101.4 
Analyst – 4 99.6 101.3 
 
Acceptance Criteria: 
 The % recovery at each level and mean recovery should be in between 
98.0% to 102%. 
SYSTEM SUITABILITY 
        To verify whether the analytical system is working properly or it can give 
accurate and precise results, the system suitability parameters are to be set. 
Inject separately 20 L each of the following solutions into the HPLC. 
Standard preparation: 
                                             Weigh accurately about  50mg of Metformin, 
50mg  Sitagliptin working standard to a 100ml volumetric flask.Dissolve it 
completely and sonicate it. Make up to 100ml mobile phase. Take 3ml from the 
above flask and make up to 50ml with mobile phase. 
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Table - 12 
System 
suitability 
parameters 
Metformin HCL  Sitagliptin  
Tailing factor 1.056 1.000 
No. of 
theoretical             
plates 
9226 11340 
Resolution - 13.861 
 
Acceptance criteria as follows: 
In the chromatogram obtained with Standard, 
 The % RSD of area of Metformin HCL and Sitagliptin  in replicate 
injections of standard solution should not be more than 2.0. 
 The tailing factor of Metformin HCL and Sitagliptinpeak should not be 
more than 2.0 
 The theoretical plates of Metformin HCL and Sitagliptin peak should be 
more than 2000. 
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RESULT AND DISCUSSION 
 
           The working condition for the RP-HPLC method was established for 
Metformin HCL and Sitagliptin  then was applied on pharmaceutical dosage 
forms. A simple reverse phase liquid chromatographic method has been 
developed and subsequently validated. 
           The separation method was carried out by using a mobile phase 
consisting of 0.02M dipotassium hydrogen phosphate and acetonitrile in the 
ratio 55:45.the detection was carried out by using UV – Visible SPD 20 A at 
240nm.The column was phenominex Gemini C18 (250×4.6mm×5µ).The flow 
rate was selected as 1ml/min. 
           The retention time of Metformin HCL and Sitagliptin was found to be 
4.285 and 7.485 respectively. The asymmetry factor or tailing  1.008 and 
1.011respectively, which indicates symmetrical nature of the peak. The number 
of theoretical plates of Metformin HCL and Sitagliptin was found to be 8840 
and 12044 respectively, which indicates the efficiency performance of the 
column. 
          From the linearity studies, specified concentration levels were 
determined .It was observed that Metformin HCL and Sitagliptin  was linear in 
the range of 80% to 120% for the target concentration .The linearity range of 
10-50mg/ml for Metformin HCL and Sitagliptin  were found to obey linearity 
with a correlation coefficient of 0.999 and 0.999 respectively. 
                    The validation of proposed method was verified by recovery 
studies. The percentage recovery range was found to be satisfied which 
represent in results. The robustness studies were performed by changing the pH 
and wavelength. The ruggedness study was also performed. 
         The analytical method validation was carried as per ICH guidelines and 
given below are the tables are the summary of the result. 
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S.No PARAMETERS LIMIT OBSERVATIONS 
PASSES/ 
FAILS 
1 Specificity 
No Interferences at 
retention time of 
the analyte peak. 
No Interference at 
retention time of the 
analyte peak 
Passes 
2 System 
Precision 
RSD NMT 2.0% 
Metforminn:0.3397% 
Sitagliptin:0.385 
Passes 
3 Method 
Precision 
RSD NMD 2.0% 
Metforminn:0.46% 
Sitagliptin:0.25% 
 
Passes 
4 Linearity of 
detector response 
Correlation co-
efficient NLT 
0.999 
Metforminn:0.999 
Sitagliptin:0.999 
Passes 
5 Accuracy % Recovery range 98-102% 
Metforminn:99.59-
100.71% 
Sitagliptin:99.11-
101.18% 
Passes 
6 Ruggedness % Recovery range 98-102% Within limits Passes 
7 Robustness RSD NMT 2.0% Within limits Passes 
8 
Limit of 
detection 
(LOD) 
Based on SD of the 
Response and slope 
Metforminn 
:1.052µg/ml  
Sitagliptin:7.10µg/ml 
 
Passes 
9 
Limit 
quantitation 
(LOQ) 
Based on SD of the 
Response and slope 
Metforminn :5.7µg/ml  
Sitagliptin 3.4µg/ml 
passes 
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SUMMARY AND CONCLUSION 
RP-HPLC method was developed. It was validated for the estimation of 
Metformin HCL and Sitagliptin  in tablet dosage form using HPLC Shimadzu 
Prominence with UV-Visible SPD 20A Detector and Phenominex C18 
(250x4.6mm, 5µ) column, injection of 20 µl is injected and eluted with the 
mobile phase of dipotassium hydrogen phosphate buffer,  and acetonitrile in the 
ratio 55:45, which was pumped at a flow rate of 1ml at 260 nm. The peak of 
Metformin HCL and Sitagliptin are found well separated at 4.285 and 7.485 
respectively. The developed method was validated for various parameters as 
per ICH guidelines like Accuracy, Precision, Linearity, Specificity, 
Ruggedness, Robustness, LOQ and LOD. 
 The analytical method validation of Metformin HCL and Sitagliptin by 
RP HPLC method was found to be satisfactory and could be used for the 
routine pharmaceutical analysis of Metformin HCL and Sitagliptin . 
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